Home › Funds › MFS Investment Management › BSX

MFS Investment Management position in BSX

BOSTON SCIENTIFIC CORP · Health Care

MFS Investment Management reported holding 43,054,393 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$2.29B, representing 0.78% of its reported portfolio and ranking #22 among its reported holdings. MFS Investment Management has disclosed BSX holdings in 34 of the last 47 reported quarters, going back to Q1 2015.

Latest position (Q3 2026)43.05M sh
Reported value held$2.29B
Portfolio Weight0.78%
First reportedQ1 2015
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How MFS Investment Management's BSX position evolved

MFS Investment Management first disclosed a stake in BSX in Q1 2015 at 1,042,321 shares (US$18.50B). Across 34 filings, MFS Investment Management increased the stake 16 time(s), trimmed it 16 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 43,054,393 shares valued at US$2.29B — an increase of 18,195,202 shares quarter over quarter.. Notable position changes include a 165% increase in Q4 2018, a 119% increase in Q1 2020, a 126% increase in Q2 2026 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2015 1.04M $18.50B New
Q3 2018 3.00M $115.62M New
Q4 2018 7.94M $280.77M Add
Q1 2019 11.38M $436.95M Add
Q2 2019 11.60M $498.78M Add
Q3 2019 12.23M $497.56M Add
Q4 2019 13.58M $614.21M Add
Q1 2020 29.73M $970.22M Add
Q2 2020 43.02M $1.51B Add
Q3 2020 43.33M $1.66B Add
Q4 2020 49.03M $1.76B Add
Q1 2021 82.66M $3.19B Add
Q2 2021 84.42M $3.61B Add
Q3 2021 83.80M $3.64B Reduce
Q4 2021 85.53M $3.63B Add
Q1 2022 84.17M $3.73B Reduce
Q2 2022 83.61M $3.12B Reduce
Q3 2022 84.09M $3.26B Add
Q4 2022 81.98M $3.79B Reduce
Q1 2023 79.53M $3.98B Reduce
Q2 2023 69.14M $3.74B Reduce
Q3 2023 62.53M $3.30B Reduce
Q4 2023 57.18M $3.31B Reduce
Q1 2024 46.61M $3.19B Reduce
Q2 2024 31.79M $2.45B Reduce
Q3 2024 25.67M $2.15B Reduce
Q4 2024 19.66M $1.76B Reduce
Q1 2025 16.52M $1.67B Reduce
Q2 2025 12.86M $1.38B Reduce
Q3 2025 10.37M $1.01B Reduce
Q4 2025 9.09M $866.31M Reduce
Q1 2026 11.00M $716.92M Add
Q2 2026 24.86M $1.50B Add
Q3 2026 43.05M $2.29B Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 17 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), D. E. Shaw & Co (US$1.16B), Janus Henderson Group (US$1.04B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has MFS Investment Management held BSX?

MFS Investment Management has disclosed BSX holdings in 34 of the last 47 reported quarters, going back to Q1 2015.

What is MFS Investment Management's current position in BSX?

As of Q3 2026, MFS Investment Management holds 43.05M shares of BSX (BOSTON SCIENTIFIC CORP), valued at $2.29B, representing 0.78% of its reported portfolio and ranking #22.

Has MFS Investment Management been buying or selling BSX?

In the latest 13F filing (Q3 2026), MFS Investment Management increased its position in BSX.

Which other funds hold BSX?

Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co, Janus Henderson Group, among 17 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.